Global Whole Exome Sequencing Market Size, Share, Growth Analysis, By Technology(Targeted Sequencing, Whole Exome Sequencing and Others), By Application(Oncology, Rare Diseases), By End-user(Research Centers and Academic Institutions, Hospitals and Clinics) - Industry Forecast 2024-2031

Whole Exome Sequencing Market size was valued at USD 360.02 million in 2021 and is poised to grow from USD 422.95 million in 2022 to USD 1534.62 million by 2030, growing at a CAGR of 17.48% during the forecast period (2023-2030).

The market has witnessed significant growth potential due to various factors, including the development of new technologies, increased applications in research and diagnostics, and a reduction in costs associated with these technologies. The demand for precise and early detection methods for genetic and chronic diseases has also contributed to the expansion of the market. Consequently, the utilization of advanced sequencing technologies has greatly propelled market growth, as medical professionals and researchers employ whole exome sequencing to identify genetic variations related to different diseases and develop personalized treatments based on patients' genomic data. A study published in the Journal of Cancer in 2020 exemplifies how exome sequencing has been employed to identify mutations in patients with advanced cancer, predicting their response to immunotherapy and demonstrating its potential to revolutionize personalized medicine. The global demand for whole exome sequencing products is rapidly increasing due to several key factors, primarily driven by the decreasing cost associated with advancements in automation, data analysis tools, and various technologies. These advancements have made whole exome sequencing more accessible and affordable for healthcare facilities and researchers to study genetic information. For example, a partnership between a Chinese healthcare provider and BGI Genomics was established in 2022 to offer whole exome sequencing services for cancer patients, aiming to gain a better understanding of cancer genetics and provide personalized treatment options. Such collaborations highlight the growing popularity of whole exome sequencing in clinical settings due to its affordability and accessibility. The utilization of this technology by medical professionals for diagnosing and treating a range of diseases is increasing, indicating a promising future for genetic medicine and whole exome sequencing. Additionally, the market has experienced significant growth due to the demand for personalized care. Medical professionals can now utilize whole exome sequencing to customize treatment recommendations based on a patient's unique genetic alterations and susceptibility to diseases. This allows healthcare providers to offer specialized and more effective treatments by thoroughly examining a patient's DNA. For example, Natera's Signatera, a test based on whole exome sequencing, has been designated as a breakthrough device by the FDA. This test assists in monitoring tumor recurrence, allowing patients who have undergone treatment for solid tumors to track the presence of any residual disease. By analyzing circulating tumor DNA, Signatera identifies genetic changes associated with cancer and tracks the patient's response to therapy. The FDA's recognition of Signatera as a breakthrough device emphasizes the potential of exome sequencing-based diagnostics in cancer identification and treatment. The whole exome sequencing industry is growing due to the increasing demand for personalized treatment. Further market growth is anticipated with the introduction of new diagnostics and assays. Through whole exome sequencing, medical professionals can now identify a patient's specific genetic anomalies and disease risk factors, enabling them to design treatment plans tailored to each individual's needs. This advancement in individualized medicine holds the potential to revolutionize healthcare practices.

US Whole Exome Sequencing Market is poised to grow at a sustainable CAGR for the next forecast year.